The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agendia; Amgen; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene/Jazz; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Lilly; MSD; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; Riemser; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Lilly; MSD; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; Riemser; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
Speakers' Bureau - Agendia; Amgen; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Lilly; MSD; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; Riemser; Roche; Sandoz/Hexal; Seattle Genetics/Astellas; Tesaro; Teva
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Lilly; MSD; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; Riemser; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.
 
Nadia Harbeck
Honoraria - Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Sandoz; Seagen
Research Funding - Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Oleg Gluz
Honoraria - AstraZeneca; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Amgen; Daiichi Sankyo; Genomic Health; Merck Sharp & Dohme; Roche
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; Roche
 
Matthias Christgen
No Relationships to Disclose
 
Monika Graeser
No Relationships to Disclose
 
Felix Hilpert
No Relationships to Disclose
 
Katja Krauss
Honoraria - Celgene; Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; Pfizer
Research Funding - Myelo Therapeutics GmbH; Novartis; Roche
 
Hans Heinrich Kreipe
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Genomic Health; Novartis; Pfizer; Pfizer; Roche Pharma AG
 
Ulrike Nitz
Honoraria - Agendia; Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche/Genentech; Teva
Consulting or Advisory Role - Genomic health; Roche
Research Funding - Agendia (Inst); Amgen (Inst); Celgene (Inst); Genomic Health (Inst); Genomic Health (Inst); NanoString Technologies (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - Genomic Health
Travel, Accommodations, Expenses - Genomic Health; Pfizer; Roche
 
Ronald E. Kates
Honoraria - Amgen (I); Celgene (I); Genomic Health (I); NanoString Technologies (I); Novartis (I); Pfizer (I); Roche (I)
Consulting or Advisory Role - Agendia (I); AstraZeneca (I); Celgene (I); Daiichi Sankyo (I); Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Odonate Therapeutics (I); Pfizer (I); Roche/Genentech (I); Sandoz (I); Seagen (I)
 
Timo Schinkoethe
No Relationships to Disclose
 
Rachel Wuerstlein
No Relationships to Disclose
 
Sherko Kuemmel
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; MSD Oncology; Novartis; Pfizer; pfm medical; Puma Biotechnology; Roche/Genentech; SOMATEX
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche